464 related articles for article (PubMed ID: 21502598)
21. Depressive symptoms, neurocognitive impairment, and adherence to highly active antiretroviral therapy among HIV-infected persons.
Ammassari A; Antinori A; Aloisi MS; Trotta MP; Murri R; Bartoli L; Monforte AD; Wu AW; Starace F
Psychosomatics; 2004; 45(5):394-402. PubMed ID: 15345784
[TBL] [Abstract][Full Text] [Related]
22. Effectiveness and safety of didanosine, lamivudine and efavirenz versus zidovudine, lamivudine and efavirenz for the initial treatment of HIV-infected patients from the Spanish VACH cohort.
Crespo M; Ribera E; Suárez-Lozano I; Domingo P; Pedrol E; López-Aldeguer J; Muñoz A; Viladés C; Sánchez T; Viciana P; Teira R; García-Alcalde ML; Vergara A; Lozano F; Galindo MJ; Cosin J; Roca B; Terrón A; Geijo P; Vidal F; Garrido M;
J Antimicrob Chemother; 2009 Jan; 63(1):189-96. PubMed ID: 18988678
[TBL] [Abstract][Full Text] [Related]
23. A comparison of neuropsychiatric adverse events during 12 weeks of treatment with etravirine and efavirenz in a treatment-naive, HIV-1-infected population.
Nelson M; Stellbrink HJ; Podzamczer D; Banhegyi D; Gazzard B; Hill A; van Delft Y; Vingerhoets J; Stark T; Marks S
AIDS; 2011 Jan; 25(3):335-40. PubMed ID: 21150563
[TBL] [Abstract][Full Text] [Related]
24. Baseline CD4(+) T-cell count and cardiovascular risk factors predict the evolution of cognitive performance during 2-year follow-up in HIV-infected patients.
Ciccarelli N; Grima P; Fabbiani M; Baldonero E; Borghetti A; Milanini B; Limiti S; Colafigli M; Tamburrini E; Cauda R; De Luca A; Di Giambenedetto S
Antivir Ther; 2015; 20(4):433-40. PubMed ID: 25504667
[TBL] [Abstract][Full Text] [Related]
25. High prevalence of HIV-associated neurocognitive disorder in HIV-infected patients with a baseline CD4 count ≤ 350 cells/μL in Shanghai, China.
Wang Z; Zheng Y; Liu L; Shen Y; Zhang R; Wang J; Lu H
Biosci Trends; 2013 Dec; 7(6):284-9. PubMed ID: 24390367
[TBL] [Abstract][Full Text] [Related]
26. Plasma concentrations of efavirenz are associated with body weight in HIV-positive individuals.
Poeta J; Linden R; Antunes MV; Real L; Menezes AM; Ribeiro JP; Sprinz E
J Antimicrob Chemother; 2011 Nov; 66(11):2601-4. PubMed ID: 21890538
[TBL] [Abstract][Full Text] [Related]
27. Characterization of HIV-Associated Neurocognitive Disorders among individuals starting antiretroviral therapy in South Africa.
Joska JA; Westgarth-Taylor J; Myer L; Hoare J; Thomas KG; Combrinck M; Paul RH; Stein DJ; Flisher AJ
AIDS Behav; 2011 Aug; 15(6):1197-203. PubMed ID: 20614176
[TBL] [Abstract][Full Text] [Related]
28. Once-daily highly active antiretroviral therapy for HIV-infected children: safety and efficacy of an efavirenz-containing regimen.
Scherpbier HJ; Bekker V; Pajkrt D; Jurriaans S; Lange JM; Kuijpers TW
Pediatrics; 2007 Mar; 119(3):e705-15. PubMed ID: 17308244
[TBL] [Abstract][Full Text] [Related]
29. Determining optimal impairment rating methodology for a new HIV-associated neurocognitive disorder screening procedure.
Kamminga J; Bloch M; Vincent T; Carberry A; Brew BJ; Cysique LA
J Clin Exp Neuropsychol; 2017 Oct; 39(8):753-767. PubMed ID: 28052738
[TBL] [Abstract][Full Text] [Related]
30. Quality of life and depression among HIV-infected patients receiving efavirenz- or protease inhibitor-based therapy in Senegal.
Poupard M; Ngom Gueye NF; Thiam D; Ndiaye B; Girard PM; Delaporte E; Sow PS; Landman R
HIV Med; 2007 Mar; 8(2):92-5. PubMed ID: 17352765
[TBL] [Abstract][Full Text] [Related]
31. Neurocognitive impairment and neuroCART.
Wright E
Curr Opin HIV AIDS; 2011 Jul; 6(4):303-8. PubMed ID: 21546833
[TBL] [Abstract][Full Text] [Related]
32. Efavirenz is associated with severe vitamin D deficiency and increased alkaline phosphatase.
Welz T; Childs K; Ibrahim F; Poulton M; Taylor CB; Moniz CF; Post FA
AIDS; 2010 Jul; 24(12):1923-8. PubMed ID: 20588161
[TBL] [Abstract][Full Text] [Related]
33. Depressive symptoms and neurocognitive performance among HIV-infected women.
Fialho RM; Pereira M; Mendonça N; Ouakinin S
Women Health; 2013; 53(2):117-34. PubMed ID: 23517511
[TBL] [Abstract][Full Text] [Related]
34. Effect of aging and human immunodeficiency virus infection on cognitive abilities.
Ciccarelli N; Fabbiani M; Baldonero E; Fanti I; Cauda R; Di Giambenedetto S; Silveri MC
J Am Geriatr Soc; 2012 Nov; 60(11):2048-55. PubMed ID: 23110543
[TBL] [Abstract][Full Text] [Related]
35. High frequency of vitamin D deficiency in HIV-infected patients: effects of HIV-related factors and antiretroviral drugs.
Allavena C; Delpierre C; Cuzin L; Rey D; Viget N; Bernard J; Guillot P; Duvivier C; Billaud E; Raffi F
J Antimicrob Chemother; 2012 Sep; 67(9):2222-30. PubMed ID: 22589455
[TBL] [Abstract][Full Text] [Related]
36. Efavirenz versus boosted atazanavir or zidovudine and abacavir in antiretroviral treatment-naive, HIV-infected subjects: week 48 data from the Altair study.
Puls RL; Srasuebkul P; Petoumenos K; Boesecke C; Duncombe C; Belloso WH; Molina JM; Li L; Avihingsanon A; Gazzard B; Cooper DA; Emery S;
Clin Infect Dis; 2010 Oct; 51(7):855-64. PubMed ID: 20735258
[TBL] [Abstract][Full Text] [Related]
37. Neurocognitive impairment among HIV-positive individuals in Botswana: a pilot study.
Lawler K; Mosepele M; Ratcliffe S; Seloilwe E; Steele K; Nthobatsang R; Steenhoff A
J Int AIDS Soc; 2010 Apr; 13():15. PubMed ID: 20406460
[TBL] [Abstract][Full Text] [Related]
38. Duration of first-line antiretroviral therapy with tenofovir and emtricitabine combined with atazanavir/ritonavir, efavirenz or lopinavir/ritonavir in the Italian ARCA cohort.
Di Biagio A; Prinapori R; Giannarelli D; Maggiolo F; Di Giambenedetto S; Borghi V; Penco G; Cicconi P; Francisci D; Sterrantino G; Zoncada A; Monno L; Capetti A; Giacometti A;
J Antimicrob Chemother; 2013 Jan; 68(1):200-5. PubMed ID: 22915463
[TBL] [Abstract][Full Text] [Related]
39. Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virological suppression.
Gulick RM; Lalama CM; Ribaudo HJ; Shikuma CM; Schackman BR; Schouten J; Squires KE; Koletar SL; Pilcher CD; Reichman RC; Klingman KL; Kuritzkes DR
AIDS; 2007 Apr; 21(7):813-23. PubMed ID: 17415036
[TBL] [Abstract][Full Text] [Related]
40. Long-term safety and efficacy of a once-daily regimen of emtricitabine, didanosine, and efavirenz in HIV-infected, therapy-naive children and adolescents: Pediatric AIDS Clinical Trials Group Protocol P1021.
McKinney RE; Rodman J; Hu C; Britto P; Hughes M; Smith ME; Serchuck LK; Kraimer J; Ortiz AA; Flynn P; Yogev R; Spector S; Draper L; Tran P; Scites M; Dickover R; Weinberg A; Cunningham C; Abrams E; Blum MR; Chittick GE; Reynolds L; Rathore M;
Pediatrics; 2007 Aug; 120(2):e416-23. PubMed ID: 17646352
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
